<unk>  is indicated as monotherapy for adults with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy of at least ten years and clinical stage T1c or T2a; Gleason score ≤ 6, based on high-resolution biopsy strategies; prostate-specific antigen (PSA) ≤ 10ng/mL; three positive cancer cores with a maximum cancer core length of 5mm in any one core or 1-2 positive cancer cores with ≥ 50% cancer involvement in any one core or a PSA density ≥ 0.15ng/mL/cm3.
Padeliporfin
Etalocib
Afamelanotide
Epoetin alfa
Asfotase alfa
Bisantrene
Efgartigimod alfa
Pegvaliase